Gainesville, FL19 Active Studies

Rheumatoid Arthritis Clinical Trials in Gainesville, FL

Find 19 actively recruiting rheumatoid arthritis clinical trials in Gainesville, FL. Connect with local research sites and explore new treatment options.

19
Active Trials
16
Sponsors
4,893
Enrolling

Recruiting Rheumatoid Arthritis Studies in Gainesville

RecruitingGainesville, FLNCT06480383

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in ...

705 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingGainesville, FLNCT06701903

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Stati...

570 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingGainesville, FLNCT05816382

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861....

500 participants
Takeda
View Study Details
RecruitingGainesville, FLNCT05421741

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

This prospective randomized clinical trial will compare outcomes between patients treated primarily with a prophylactic antibiotic coated nail and those treated with traditional standard of care intra...

484 participants
Wake Forest University Health Sciences
View Study Details
RecruitingGainesville, FLNCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in ...

400 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingGainesville, FLNCT05615844

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participant...

312 participants
University of Maryland, Baltimore
View Study Details
RecruitingGainesville, FLNCT06635148

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....

311 participants
Janssen Research & Development, LLC
View Study Details
RecruitingGainesville, FLNCT06213649

Parasitic Ulcer Treatment Trial

The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regime...

232 participants
Jeremy Keenan, MD, MPH
View Study Details
RecruitingGainesville, FLNCT06777901

Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone

The goal of this clinical trial is to learn if the Auryon Atherectomy System with balloon angioplasty safe and effective in treating lower limb blockages. The main question it aims to answer is: Is tr...

224 participants
Angiodynamics, Inc.
View Study Details
RecruitingGainesville, FLNCT05197270

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-1...

215 participants
4D Molecular Therapeutics
View Study Details
RecruitingGainesville, FLNCT07038200

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)...

200 participants
Avidity Biosciences, Inc.
View Study Details
RecruitingGainesville, FLNCT06008795

BLOCK-SAH - PPF-Block for Post-SAH Headache

BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injecti...

195 participants
University of Florida
View Study Details
RecruitingGainesville, FLNCT05263934

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy....

160 participants
GlaxoSmithKline
View Study Details
RecruitingGainesville, FLNCT07197034

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us ...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingGainesville, FLNCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingGainesville, FLNCT03394365

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferati...

66 participants
Pierre Fabre Medicament
View Study Details
RecruitingGainesville, FLNCT06660667

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneratio...

66 participants
Sanofi
View Study Details
RecruitingGainesville, FLNCT05819866

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy....

40 participants
Minoryx Therapeutics, S.L.
View Study Details
RecruitingGainesville, FLNCT05714969

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1)...

33 participants
Takeda
View Study Details

About Rheumatoid Arthritis Clinical Trials in Gainesville

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.

There are currently 19 rheumatoid arthritis clinical trials recruiting participants in Gainesville, FL. These studies are seeking a combined 4,893 participants. Research is being sponsored by Intra-Cellular Therapies, Inc., Takeda, Wake Forest University Health Sciences and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Rheumatoid Arthritis Clinical Trials in Gainesville — FAQ

Are there rheumatoid arthritis clinical trials in Gainesville?

Yes, there are 19 rheumatoid arthritis clinical trials currently recruiting in Gainesville, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Gainesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gainesville research site will contact you about next steps.

Are clinical trials in Gainesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gainesville studies also compensate for your time and travel.

What rheumatoid arthritis treatments are being tested?

The 19 active trials in Gainesville are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.

Data updated March 2, 2026 from ClinicalTrials.gov